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Abstract: Approximately 18% of acute myeloid leukemia (AML) cases express a fusion transcript. 
However, few fusions are recurrent across AML and the identification of these rare chimeras is of 
interest to characterize AML patients. Here, we studied the transcriptome of 8 adult AML patients 
with poorly described chromosomal translocation(s), with the aim of identifying novel and rare 
fusion transcripts. We integrated RNA-sequencing data with multiple approaches including 
computational analysis, Sanger sequencing, fluorescence in situ hybridization and in vitro studies 
to assess the oncogenic potential of the ZEB2-BCL11B chimera. We detected 7 different fusions with 
partner genes involving transcription factors (OAZ-MAFK, ZEB2-BCL11B), tumor suppressors 
(SAV1-GYPB, PUF60-TYW1, CNOT2-WT1) and rearrangements associated with the loss of NF1 
(CPD-PXT1, UTP6-CRLF3). Notably, ZEB2-BCL11B rearrangements co-occurred with FLT3 
mutations and were associated with a poorly differentiated or mixed phenotype leukemia. 
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Although the fusion alone did not transform murine c-Kit+ bone marrow cells, 45.4% of 14q32 non-
rearranged AML cases were also BCL11B-positive, suggesting a more general and complex 
mechanism of leukemogenesis associated with BCL11B expression. Overall, by combining different 
approaches, we described rare fusion events contributing to the complexity of AML and we linked 
the expression of some chimeras to genomic alterations hitting known genes in AML. 
Keywords: acute myeloid leukemia; rare fusion genes; ZEB2-BCL11B 
 
1. Introduction 
Fusion genes represent a major criterion of diagnosis and prognostic risk stratification in the 
European Leukemia Net 2017 classification of AML [1], where approximately 18% of cases are 
characterized by the presence of a known fusion genes as the main driver event [2]. 
The chromosomal translocation t(15;17), leads to the expression of a PML-RARA chimera and 
characterizes patients with acute promyelocytic leukemia, who generally have favourable prognosis. 
AMLs expressing the transcripts RUNX1-RUNXT1 and CBFβ-MYH11, associate with the t(8;21) and 
inv(16), respectively, are also known to confer a favourable prognosis. However, the t(6;9), 
inv(3)/t(3;3), t(v;11q23.3) and t(9;22) abnormalities result in the expression of DEK-NUP214, 
GATA2/MECOM fusions, KMT2A-fusions and BCR-ABL1, respectively, all of which correlate with a 
poor outcome [1]. 
Moreover, fusion genes resulting from chromosomal translocations are common features of 
other haematological cancers and, due to their unique presence in cancer tissues, they represent 
extremely attractive therapeutic targets. The paradigm is BCR-ABL1 in chronic myeloid leukemia 
(CML) and Philadelphia-positive acute lymphoblastic leukemia (ALL), which drives leukemogenesis 
and can be targeted by a specific therapy capable of reversing the leukemic phenotype [3,4]. 
Whole genome sequencing and RNA sequencing (RNA-seq) approaches have allowed the 
identification of several novel fusions in acute leukemia that remained cryptic by routine cytogenetic 
analysis. The Cancer Genome Atlas Research Network identified 118 fusions in 179 AML patients by 
RNA-seq, with an average of 1.5 fusions per patient [5]. Moreover, it has been shown that normal 
karyotype AMLs are characterized by the presence of several chimeras, mainly deriving from 
adjacent genes located on the same chromosome and with complex patterns of partner gene 
orientation [6]. Previous studies discovered the NUP98-PHF23 fusion gene in paediatric 
cytogenetically normal AML carrying a cryptic chromosomal translocation between chromosomes 11 
and 17 [7,8]. Chromosomal translocations leading to the expression of fusion transcripts are also an 
hallmark of ALL and the detection of such aberrations is an example of how genomic analysis can 
dramatically improve the sub-classification of patients [9]. 
Hence, the identification of fusion events, even when shared by a small subgroup of poorly 
characterized patents, may be of clinical significance. We thus performed RNA-seq on samples from 
eight AML patients characterized by the presence of a rare or poorly described chromosomal 
translocation(s) to identify novel fusion transcripts with a potential leukemogenic/pathogenetic role. 
We also combined different approaches including cytogenetic, RNA-seq, bioinformatics analysis and 
literature mining to help in understating the pathogenetic role of the identified novel and rare fusion 
events. We validated the presence of nine fusion genes involving either transcription factors, tumor 
suppressors, or associated with a loss event of candidate genes in AML. We found that the landscape 
of alterations in AML is not limited to known genes, and that fusion genes, albeit rare, may play an 
important role in the disease development. 
2. Results 
2.1. RNA-Seq Cohort Selection 
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We screened the biobank of AML biological samples collected at our Institution between 2010 
and 2015. We identified 46 patients (<1% of total cases) carrying a rare chromosomal translocation 
(i.e., individual incidence <1% [1]) as the sole alteration (13%) or in association with other 
chromosomal abnormalities (87%). Based on the availability of biological material, eight samples 
collected at diagnosis or relapse were selected for RNA-seq (Table 1). According to the 2016 revision 
of WHO classification of myeloid malignancies [10], our cohort included one AML with 
inv(16)(p13q22) (sample #84), one AML with mutated NPM1 (sample #63569), one AML without 
maturation (sample #59810), one AML with maturation (sample #20), one AML with mutated RUNX1 
(sample #21) and three AML cases with myelodysplasia-related changes (samples #32, #68187 and 
#125). Patients had an average of three mutations per case (range: 1–5). Recurrently mutated genes in 
our cohort included DNMT3A (n = 2), FLT3 (n = 3), IDH2 (n = 2), KDM6A (n = 2) and TET2 (n = 2). All 
the molecular alterations in myeloid-related genes are listed in Table S2. 
2.2. Identification and Validation of Fusions Genes 
Among fusions detected by the RNA-seq analysis, we selected 19 for further validation by RT-
PCR and Sanger sequencing (Table S3). Of these, 10 were successfully validated, including the known 
chimera CBFβ-MYH11 (53% of selected fusions, Figure 1, Tables 2,S2). No chimeras were detected 
and/or confirmed in samples #32 and #63569. The biological information on the putative function of 
the novel chimeric proteins is described in Table 2. Specifically, a new in-frame fusion gene was 
identified in sample #20: CPD-PXT1[11] (tier 1, Figure 1), which is hypothesized to be the reciprocal 
fusion product of a t(6;17)(p21;q11) translocation (Figure S1A). CPD encodes for a 
metallocarboxypeptidase and it maps in chromosome 17q11, approximately 625 Kb upstream NF1. 
Copy number analysis from SNParray data revealed that CPD had complex rearrangements 
including a copy number loss of approximately 2 Mb, from chr17:2872554, which maps in the intron 
2-3 of CPD, to chr17: 30768221, including the entire NF1 gene (chr17:29419945-29706695, Figure S2A). 
 
Figure 1. Schematic representation of validated fusion genes. Reading frames, tier, samples in which 
they were detected and chromosomal location of partner genes are reported. For the ZEB2-BCL11B 
transcript, we detected three splicing isoforms and the reciprocal transcript BCL11B-ZEB2. 
Sample #20 was also characterized by the in-frame transcript SAV1-GYPB, which remained 
cryptic at cytogenetic analysis. The driver score (DS) predicted by Pegasus (DS=0.87) identified the 
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chimera as a potential driver of leukemogenesis [12,13] (tier 2, Figure 2A and S1B). In sample #21 we 
identified a novel fusion event between chromosomes 19 and 7, involving the genes OAZ1 [14] and 
MAFK [15] (tier 2, Figures 1,2B,S1C). 
 
Figure 2. Representation of the domains of the in-frame fusion genes. (A) The breakpoint of SAV1-
GYPB mapped on chromosome 14p22, exon 2 of SAV1 (NM_021818) and chromosome 4q31, exon 2 
of GYPB (NM_002100, Figure S1B). In the putative fusion protein, SAV1 lost the stabilization and 
interaction domains including the WW domain and the coiled-coil domain, while GYBP lost the N-
terminal domains and retained the dimeric transmembrane domain. (B) The breakpoint of OAZ1-
MAFK mapped in exon 1 of OAZ1 (NM_004152), which encodes for a polyamine sensing region and 
a proteasome interaction domain. The breakpoint at 3’ mapped in exon 2 of MAFK (NM_002360), 
which, together with exon 3, encodes for the bZIP domain. The putative chimeric protein was formed 
by the sensing regions of polyamine that normally controls the transcription of OAZ1, and the bZIP 
domain of MAFK. (C) The breakpoint of the fusion ZEB2-BCL11B mapped in exon 2 of ZEB2 
(NM_014795) and exon 2 of BCL11B (NM_00128223). Twenty-four residues of ZEB2 and 803 out of 
823 residues of BCL11B formed the fusion protein. The codon 20 of BCL11B was the first involved in 
the fusion and it encoded for an alanine instead of a proline, due to a single nucleotide substitution 
at the breakpoints junctions (yellow dot). 
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We validated the out-of-frame fusion UTP6-CRLF3 [16,17] in sample #68187 (tier 3 Figure 1,S1D). 
UTP6 and CRLF3 mapped on the minus strand of chromosome 17q11 (chr17:30188190-30230729 and 
chr17:29107702-29153778, respectively). These genes flanked the NF1 locus and the rearrangement 
suggested the presence of a 1 Mb copy number loss, which encompasses the NF1 gene. We also 
confirmed the presence of the out-of-frame fusion PUF60-TYW1 [18–20] in sample #125 (tier 3 Figures 
1,S1E). Sample #59810 showed the CNOT2-WT1 [2,21–23] chimera, which is a novel out-of-frame 
fusion (tier 1, Figures 1,S1F) related to t(11;12)(p15;q22) translocation, identified by cytogenetic 
analysis. The breakpoint mapped in the forward strand of chromosome 12 and the reverse strand of 
chromosome 11. We also detected a variant that mapped in exon 3 of a non-coding transcript of CNOT2 
(NR_037615) . The partner genes mapped at opposite strands, the CNOT2 and WT1 sequence thus 
displayed a conserved and inverted sequence orientation, respectively. 
In addition to the CNOT2-WT1 rearrangement, sample #59810 carried the fusion transcript 
ZEB2-BCL11B [24–26] (tier 1, Figures 1,2C,S1G), which is an in-frame fusion and a rare event in AML 
associated with t(2;14)(q22.3;q32.2)18. Of note, we identified three splicing isoforms (Figure S1H–I), 
two of which have never been reported before. The type 1 isoform was the full-length chimera that 
retained all exons involved in the translocation. The type 2 isoform was formed by fusion of the 
junction of exon 2 of ZEB2 and exon 3 of BCL11B. In the type 3 isoform, exon 2 and 3 of BCL11B were 
removed, resulting in a smaller transcript encoded by exon 2 of ZEB2 and exon 4 of BCL11B. The 
reciprocal fusion transcript, formed by exon 1 of BCL11B and exon 3 to 10 of ZEB2, was also detected 
and validated (Figure S1J). Details for each chimera are reported in Figure 1, Tables 2,S3. 
2.3. Expression of Genes Involved in Fusions and Frequency of Rearrangments Across Cancers 
We evaluated the expression of each gene involved in the fusions by comparing its expression 
to the mean expression of the same gene in wild-type patients of the cohort (Figure S3A). The genes 
with the most variable expression between fused and wild-type patients were CRLF3, CNOT2 and 
WT1. However, due to the limited number of samples, we could not perform additional statistical 
analysis to test the significance of our data. 
To define the transcriptional program associated with AML carrying the fusion genes, we 
selected the 1000 most variable genes (based on median absolute deviation values) and we performed 
unsupervised clustering analysis. Figure S3B showed three clusters, one of which was defined by the 
ZEB2-BCL11B rearranged case alone. The first group was characterized by the presence of the CBFB-
MYH1, OAZ1-MAFK rearranged cases (sample #84 and sample #21, respectively) and a patient 
without fusions (sample #32). The second cluster included cases characterized by PUF60-TYW1, CPD-
PXT1, SAV1-GYPB and UTP6-CRLF3 fusions. Notably, patients carrying CPD-PXT1 and UTP6-
CRLF3, which were associated with NF1 loss, clustered in this group. This cluster showed a 
heterogeneous transcriptional profile. 
Differentially up-regulated genes (n = 434, logFC > 1.5) in the first cluster were enriched for genes 
involved in the protein processing in endoplasmic reticulum pathway, spliceosome, RNA transport 
and mRNA surveillance pathway (Table S4). There were no significantly down-regulated genes in 
the first group one compared to the second one. However, larger cohorts would be required to 
confirm our signature. 
To collect more patients information, we downloaded data from the TCGA Tumour Fusion Gene 
Data Portal (https://www.tumorfusions.org/[27]) and the Mitelman Database Chromosome 
Aberrations and Gene Fusions in Cancer (https://mitelmandatabase.isb-cgc.org/). We found that 
ZEB2-BCL11B (as also reported in the manuscript) and OAZ1-MAFK fusions were previously 
annotated in two AML and one multiple myeloma, respectively. Moreover, we analysed the TCGA 
cancer data looking for genomic rearrangements (and relative frequency) of the genes involved in the 
7 fusions we detected in AML. We identified 12 genes that formed chimeras with other partners in 
different tumour types, namely CPD, PXT1, SAV1, OAZ1, MAFK, UTP6, CRLF3, TYW1, CNOT2, WT1, 
ZEB2 and BCL11B. Moreover, to better understand the role of these genes in AML, we investigated 
their expression level in the TCGA AML cohort trough the cBio data portal 
(http://www.cbioportal.org/, Table S5).  
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Table 1. Patient characteristics and number of validated fusions per patient. 
ID Karyotype main clone Karyotype second clone Karyotype other 
clones 
Blasts WHO classification Other genetic 
abnormalities 
Phase Validated 
fusion(s) 
59810 
46,XX,t(2;14)(q21;q32),t(11;12)(p15;
q22) [17] 
46,XX[3] NA 80% 
AML NOS, without 
maturation 
FLT3, TET2 Diagnosis 2 
20 46,XY,t(6;17)(p21;q11) [20] NA NA 90% 
AML NOS, with 
maturation 
NRAS, SRSF2, STAG2, 
TET2 
Diagnosis 2 
21 
46,XY,t(3;12)(p22;q24),+4,-15,+mar 
[19] 
46,XY[1] NA 80% 
AML with mutated 
RUNX1 (provisional 
entity) 
CBL, DNMT3A, IDH2, 
KDM6A, RUNX1 
Relapse 1 
32 
45,XY,der(12)t(12;18)(p13;q12),-18 
[12] 
45,XY,t(4;16)(q31;q22),der
(12)t(12;18)(p13;q12),-
18[4] 
45,XY,der(6)t(6;12;
18)(p21;p13,q12),-
18 [3]/46,XY [1] 
80% AML with MRC FLT3, WT1 Relapse 0 
84 
47,XX,+8,del(11)(p11p15),t(15;17)(
q24q25), inv(16)(p13q22) [20] 
NA NA 80% 
AML with 
inv(16)(p13.1q22) 
CUX1, NOTCH1 Diagnosis 1 
68187 
46,XX,add(8)(p23),der(16)t(1;16)(q
11;q11) [18] 
46,XX[2] NA 70% AML with MRC ETV6, KDM6A Diagnosis 1 
63569 46,XY [20] 46,XY,add(10)(p15)[9] 
46,XY,add(10)(p15)
,t(1;8)(p36;q13)[2] 
70% 
AML with mutated 
NPM1 
DNMT3A, FLT3, 
IDH2, NPM1 
Relaspe 0 
125 46,XX [11] 
44~47,XX,t(4;17)(p15;q21)
,del(5)(q13q33),-7,-
18,der(X),+1~3mar[9] 
NA 50% AML with MRC TP53 Diagnosis 1 
Sample #84: positive control; NOS= not otherwise specified; MRC = myelodysplasia-related changes. NA = not available. Numbers in squared brackets indicates the number 
of cells with the relative karyotype. 
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Table 2. Biological function of genes affected by a fusion event and their potential role in leukemogenesis. 
Sample Fusion Gene function Category Fusion protein putative function 
20 CPD-PXT1 
CPD encodes for a metallocarboxypeptidase[11]  
NF1 loss 
The breakpoint in CPD was associated with a complex 
rearrangements that involved the loss of NF1. The sample 
was also characterized by a mutation in NF1 detected by 
WES. 
The role of PXT1 is unknown 
20 SAV1-GYPB 
SAV1 is a tumor suppressor of the Hippo pathway [12] 
Tumor 
suppressor 
Loss of function of SAV1. GYBP is a sialoglycoproteins of the human erythrocyte 
membrane [13] 
21 OAZ-MAFK 
OAZ1 is an Ornithine decarboxylase (ODC) antizyme protein 
that negatively regulates ODC activity [14] Transcription 
factor 
The chimera may alter the cellular transcriptional program. 
MAFK is a transcriptional regulator with bZIP domains [15] 
68187 UTP6-CRLF3 
UTP6 is involved in nucleolar processing of pre-18S ribosomal 
RNA and centriole duplication[16] 
NF1 loss 
The rearrangement led to a CN loss involving NF1, which 
maps in the forward strand of chromosome 17: 29421945-
29709134 (GRCh37). CRLF3 is a cytokine receptor-like factor that may negatively 
regulate cell cycle progression at the G0/G1 phase[28] 
125 PUF60-TYW1 
PUF60 participates in the splicing machinery[18,20] 
Tumor 
suppressor 
PUF60 haploinsufficiency was involved in TP53-dependent 
progression of a T-cell acute lymphoblastic leukaemia[20]. TYW1 may be a component of the wybutosine biosynthesis 
pathway[19] 
59810 CNOT2-WT1 
CNOT2 encodes for a subunit of the multi-component CCR4-
NOT complex, which is involved in transcriptional regulation 
and mRNA degradation [21–23] Tumor 
suppressor 
The translocation was associated to a deletion at 5’ of WT1, 
which lead to its CN loss. 
WT1 is a transcription factor and it is recurrently altered in 
haematological malignancies, including AML[2] 
59810 
ZEB2-BCL11B and  
BCL11B-ZEB2 
ZEB2 is a transcriptional factor involved in normal and 
malignant haematopoiesis[24,25] 
Transcription 
factor 
The chimera may activate an aberrant transcriptional 
programme. BCL11B is a transcription factor and key regulator of both 
differentiation and survival of T-lymphocytes during 
thymocyte development[26] 
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Table 3. Characteristics of patients carrying the ZEB2-BCL11B rearrangement and confirmed by FISH. 
Case 
number 
Gender Age WHO classification Karyotype FISH T-cell markers BCR TCR 
11942 male 58 AML NOS 46,XY,t(2;14)(q23;q32) POSITIVE NA 
no clonality 
detected 
no clonality 
detected 
11954 male 85 
AML with mutated RUNX1 (provisional 
entity) 
46,XY,t(2;14)(q14;q32) POSITIVE NA 
no clonality 
detected 
no clonality 
detected 
11944 male 79 AUL 46,XY,t(2;14)(q21;q32) POSITIVE CD2+; CD7+; TdT+ clonal 
no clonality 
detected 
11945 male 59 T/myeloid MPAL 46,XY,t(2;14)(q22;q32) POSITIVE 
CD3+; CD7+; CD2+; 
TdT+ 
no clonality 
detected 
clonal 
59810 female 40 AML NOS, without maturation 46,XX,t(2;14)(q21;q32),t(11;12)(p15;q22) POSITIVE negative 
no clonality 
detected 
no clonality 
detected 
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The data showed that the some of the candidate genes form chimeras with a variety of partners 
in different tumor types and the most frequently rearranged genes were CPD and CNOT2. On the 
other hand, ZEB2-BCL11B was the only recurrent fusion in acute leukemias, suggesting a pro-
tumorigenic function in the hematopoietic compartment. 
2.4. Relative Frequency of ZEB2-BCL11B Chimera in Acute Leukemia 
The fusion protein ZEB2-BCL11B was previously described in AML [29] and mixed phenotype 
acute leukemias [30]. To investigate the frequency of the t(2;14)(q22.3;q32.2) translocation in AML, 
we interrogated the Mitelman Database (last update on May 21, 2018, Table S6 [31]) and found four 
AML cases [29,32–34]. Moreover, while the 14q32 region and BCL11B are known to be frequently 
altered in hematological malignancies [35], we found only three additional cases of lymphoid 
malignancies carrying the t(2;14)(q21;q32) translocation, including biphenotypic leukemia [36] and 
acute lymphoblastic leukemia [37–39]. However, ZEB2 and BCL11B involvement was confirmed only 
in one case of AML present in the database. In order to extend the screening to AML patients who 
are potential candidates on the basis of their the cytogenetic data, we performed FISH on four 
additional cases carrying t(2;14)(q14-q23;q32) and we confirmed the presence of the ZEB2-BCL11B 
fusion gene in all samples (Figure 3A). Notably, the presence of the fusion was confirmed by RNA-
seq in the sample #11945 [40]. At a genomic level, the breakpoint mapped at coordinates 
chr2:145231055-145231058 and chr14:99736728-99736731. However, it was not possible to locate the 
exact position of the breakpoint due to the presence of 3 cytosines in the region of the breakpoint, 
which could belong to either ZEB2 or BCL11B (Supplementary Figure S4A). Overall, ZEB2-BCL11B 
expressing patients (n = 5), were characterized by a median age at diagnosis of 59 years old and by 
poorly differentiated morphology (Table 3). The immunophenotypic analysis was performed in three 
patients and two of them expressed T-cell markers. In particular, patient #11944 expressed CD2, CD7 
and TdT in 94%, 82% and 26% of cells, respectively, while patient #11945 was also positive for CD3 
cytoplasmatic expression, TdT and MPO, with a diagnosis of T/myeloid mixed phenotype acute 
leukemia (T/M MPAL). Of note, patient #11944 had a diagnosis of acute undifferentiated leukemia 
(AUL) and patient #59810 was positive only for myeloid markers (CD13 and CD117). 
2.5. Specific Pattern of Mutations in Patients Carrying the ZEB2-BCL11B Chimera 
We performed targeted next-generation sequencing (NGS) on a panel of genes known to be 
involved in myeloid malignancies to characterize the mutational landscape of patients carrying the 
ZEB2-BCL11B chimera. FLT3 alterations were present in 4/5 (80%) patients considered (Table 4): two 
(40%) were characterized by the internal tandem duplication (ITD) alone with an allelic frequency > 0.5 
and two (40%) had point mutations in the tyrosine kinase domain (TKD, one and two point 
mutations, respectively) and the ITD alteration, but with an allelic frequency <0.5 (40%). Moreover, 
mutations co-occurring with the ZEB2-BCL11B transcript and the FLT3 alterations targeted TET2, 
DNMT3A, GATA2, JAK2, RUNX1 and SRSF2. Notably, we did not detect any mutation of the 
screened genes in the patient #11942, who was also negative for FLT3 aberrations. In addition, 
Immunoglobulin (IG) and T cell receptor (TCR) molecular analysis showed a clonal rearrangement 
in the IG heavy chain (IGH) locus, mapping at 14q32 in sample #11944 (AUL), which had a previous 
history of diffuse large B cell lymphoma, and a TCR rearrangement in sample #11945 (T/myeloid 
MPAL).
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Table 4. Mutational status of myeloid-related genes screened by NGS. 
A 
 ASXL1 BCOR CALR CBL CSF3R CSNK1A1 DNMT3A ETNK1 ETV6 EZH2 FLT3-TKD 
#11942 NEG NEG NEG NEG NEG NEG NEG NEG NEG NEG NEG 
#11944 NEG NEG NEG NEG NEG NEG NEG NEG NEG NEG NEG 
#11954 NEG NA NA NA NA NA NEG NA NA NA NEG 
#11945 NEG NEG NEG NEG NEG NEG POS NEG NEG NEG POS 
#59810 NEG NEG NEG NEG NEG NEG NEG NEG NEG NEG POS 
B 
FLT3-TKD mutation and VAF FLT3-ITD FLT3-ITD VAF GATA1 GATA2 IDH1 IDH2 JAK2  
NEG 
 
NEG NEG NEG NEG NEG  
POS >0,5 NEG NEG NEG NEG NEG  
POS >0,5 NA NA NEG NEG POS 
c.2516A>G, c.2503G>T; p.Asp839Gly, p.Asp835Tyr; 4%, 8% POS <0,5 NEG POS NEG NEG NEG 
c.2516A>G, p.Asp839Gly 34% POS <0,5 NEG NEG NEG NEG NEG 
C 
KIT KRAS MPL NPM1 NRAS PHF6 PTPN11 RUNX1 SETBP1 SF3B1 SRSF2 STAG2 STAT3 
NEG NEG NEG NEG NEG NEG NEG NEG NEG NEG NEG NEG NEG 
NEG NEG NEG NEG NEG NEG NEG VARIANTE VARIANTE NEG POS NA NEG 
NA NEG NA NEG NEG NA NA POS NA NEG NA NA NA 
NEG NEG NEG NEG NEG NEG NEG VARIANTE NEG NEG NEG NEG NA 
NEG NEG NEG NEG NEG NEG NEG NEG NEG NEG NEG NEG NEG 
D 
STAT5B TET2 TP53 U2AF1 WT1 ZRSR2 
NEG VARIANTE NEG NEG NEG NEG 
NEG POS NEG NEG NEG NEG 
NA NEG NEG NA NA NA 
NA NEG NEG NEG NEG NEG 
NEG POS NEG NEG NEG NEG 
NEG: negative; POS: positive; VAF: variant allele frequency; NA: data not available. 
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2.6. BCL11B Protein Expression in AML and Its Transcriptional Signature 
The pro-tumorigenic role of the ZEB2-BCL11B fusion has been previously linked to the 
overexpression of BCL11B [29,41]. Paraffin-embedded tissue was available for one of the patients 
carrying the chimera (#59810) and BCL11B expression was confirmed at protein level by 
immunohistochemistry (Figure 3B). 
 
Figure 3. Immunohistochemistry and FISH of AML cases. (A) FISH analysis using specific probe for 
ZEB2 and BCL11B flanking regions. Schematic representation of RP11-644D8 BAC probe in Spectrum 
Orange covering the 5’ region of ZEB2 and RP11-464J3 BAC probe in Spectrum Green covering the 3’ 
region of BCL11B, is shown at the top. FISH performed on metaphase spread of case #59810 showing 
an abnormal fusion pattern (1 fusion, 1 orange and 1 green) with the fusion signal indicating ZEB2-
BCL11B fusion gene on der(14) (bottom, central) and the same abnormal FISH pattern observed in 
interphase nuclei of case #11942 (bottom, right). A normal FISH pattern (2 red and 2 green signals) in 
a normal control case is shown (bottom, left). (B) Immunohistochemistry analysis of BCL11B-
expressing AML samples #59810, #57863 and #13 carrying t(2;14)(q22.3;q32.3), t(7;14)(q21q32) and no 
14q32 alteration, respectively. BCL11B expression was detected in samples regardless of the presence 
of the 14q32 alterations. The expression was limited to the nucleus and the percentage of positive 
neoplastic cells was always ≥ 50%. 
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To understand whether BCL11B expression is a more general feature of AML, we performed 
immunohistochemistry analysis of 21 additional cases of newly-diagnosed AML not carrying the 
fusion genes. We detected CD34 expression in 14/21 samples and aberrant nuclear and cytoplasmic 
nucleophosmin expression in 7/21 biopsies. BCL11B positivity was detected in 9/21 (40.9%) cases of 
AML (Table S7). BCL11B protein expression in leukemic blasts was limited to the nucleus and varied 
in strength from weak to moderate. Scattered cells with a stronger positivity could occasionally be 
seen. In positive cases, the percentage of positive neoplastic cells was always ≥50%. No significant 
association was found between BCL11B expression and AML immunohistochemical phenotype. 
In addition, BCL11B stained positive in one T/M MPAL (CD34, MPO positive, CD3 positive) and 
one AUL (CD34 positive, CD117 positive and CD2 positive) corresponding to cases #193 and #57863 
carrying BCL11B rearrangements and associated to t(6;14)(q25;q32) and t(7;14)(q21;q32), respectively 
(Table S7, Figures S4B–D). 
To identify the transcriptional signature associated with BCL11B expression in AML, we studied 
the gene expression profile (GEP) data of patients. In our cohort (n = 22), 5% of AML patients had 
higher expression of BCL11B mRNA, however 10 (45.5%) and 12 (54.5%) cases either expressed 
BCL11B protein or did not, respectively. Of note, no significant difference was observed in terms of 
mRNA expression between BCL11B+ and BCL11B− patients (mRNA data from array and qPCR, 
Supplementary Figure S5A), indicating the lack of association between BCL11B mRNA and protein 
levels. When comparing GEP according to protein expression, we identified 152 differentially 
expressed genes (p < 0.05), of which 36 and 116 were ≥ 2-fold upregulated and downregulated, 
respectively. Notably, BCL11B+ patients were enriched for downregulated genes involved in the 
innate immune response (ES = 6.3; p = 1 × 10−8), inflammatory response (ES = 5; p = 2.5 × 10−5), leukocyte 
migration (enrichment score ES = 9.1; p =1.1 × 10−4), cell adhesion (ES = 3.4; p = 0.002), leukotriene 
metabolic process (ES = 31.7; p = 0.004) and response to oxidative stress (ES = 5.8; p = 0.03, Table S8). Of 
note, among genes deregulated in the leukotriene pathway we identified ALOX5 (fold change = −4.36) 
and ALOX5AP (fold change = −2), where the loss of ALOX5 has been reported to impair leukemic 
stem cells and prevent the onset of chronic myeloid leukemia in mice [42]. 
2.7. ZEB2-BCL11B Expression Failed to Sustain Self-Renewal of Murine Hematopoietic Stem and 
Progenitor Cells 
We assessed the leukemogenic potential of the ZEB2-BCL11B fusion by analyzing its ability to 
sustain self-renewal of murine hematopoietic progenitor cells. Bone marrow (BM) c-Kit+ cells 
expressing the full-length chimera were used in colony forming unit assays. In addition, cells were 
kept in liquid culture to monitor GFP expression and ZEB2-BCL11B mRNA levels over time: GFP 
expression increased from 2.5% at day 1–43% GFP+ cells at day 14, while mRNA levels were 30-fold 
and 800-fold higher than those of the negative control at day 6 and 13, respectively, highlighting low 
but specific expression of the chimeric transcript (Figures S5B–D). No differences in term of 
clonogenic capacity were detected between cells transduced with the empty vector (negative control) 
or the ZEB2-BCL11B transcript. Moreover, regarding self-renewal capacity, no colonies were detected 
at day 14 (second re-plating) in either the negative control or cells expressing the chimera, whereas 
MLL-AF9 transduced cells (positive control) showed self-renewal capacity. 
3. Discussion 
Several studies have described a heterogeneous landscape of chimeras in AML [30,40,43,44], 
where very few fusions and genes were recurrently rearranged or altered. Here we analysed a cohort 
of AML patients characterized by the presence of a rare or never before reported chromosomal 
translocation with the aim of detecting the putative fusion gene correlated with the translocation. We 
identified novel and rare fusion events with an expected pathogenic role in adult AML patients. 
The advantages of RNA-seq in detecting fusion events rely not only on the ability to 
systematically identify fusions whose partner genes are unknown, but also to detect those 
rearrangements that remain cryptic at cytogenetic analysis (small deletions, inversions or 
duplications). In the past years, several bioinformatics tools have been established for the detection 
Cancers 2019, 11, 1951 13 of 21 
 
of fusion events in RNA-seq data. However, the output of these software is represented by a high 
number of false positive predictions. This is mainly due to systematic errors including read-through 
artefacts, reverse transcriptase template switching events or mapping biases. Moreover, fusions 
identification tools provide no information regarding the oncogenic relevance of the output fusions. 
These features make the systematic experimental validation of gene fusion lists obtained from in 
silico pipelines unfeasible. To overcome this limitation, we exploited the “downstream” tool 
FuGePrior to reduce the number of events to those highly reliable and with a putative biological 
function. FuGePrior combines results from state of the art bioinformatic tools for chimeric transcripts 
identification and prioritization, several filtering and processing steps designed on up-to-date 
literature on gene fusions and analysis of the potential functionality of the fusion according to its 
structure. This allowed us to conduct the experimental validation on a manageable list of candidates. 
Five fusion genes associated with the known cytogenetic translocations and four fusions that 
remained cryptic at the level of cytogenetic analysis were closely studied. The fusions associated with 
balanced rearrangements were: (i) two isoforms of ZEB2-BCL11B and its reciprocal BCL11B-ZEB2 
chimeric transcript associated with the translocation t(2;14)(q21-q23;q32); (ii) CNOT2-WT1 which derived 
from the translocation t(11;12); (iii) CPD-PXT1 related to the t(6;17) aberration (Figures 1,2). Further cryptic 
fusions included UTP6-CRLF3, PUF60-TYW1, SAV1-GYPB and OAZ1-MAFK (Figures 1,2). The fusions 
ZEB2-BCL11B, BCL11B-ZEB2 and OAZ1-MAFK involved genes encoding for transcription factors and 
we speculated that the putative mechanism of action of the fusion proteins may be linked to 
alterations of the transcriptional program. 
We selected the chimera ZEB2-BCL11B for functional studies due to its frequency in acute leukemia. 
The remaining fusion events were not further investigated. However, we speculate on their potential 
activity in leukemic cells according to known features of partner genes involved in the translocations. 
We associated the expression of fusion events involving genes on chromosomes 17, such as 
UTP6-CRLF3 and CPD-PXT1, to the loss of NF1. The detection of these “hidden” alterations required 
the integration of different layers of genomic data (mutation analysis and copy number alterations), 
highlighting the complexity of the genomic alterations in AML and the importance of an accurate 
characterization of each patient´s alterations to permit a personalized medicine approach. The 
consequences of the out of frame fusions CNOT2-WT1 and PUF60-TYW1 is more difficult to speculate 
on but may be related to the loss of function of WT1 (data not shown) and PUF60, respectively. 
Genomic alterations of WT1 including point mutations and small insertions and deletions have been 
reported in 5% of AML cases[2,44] and the haploinsufficiency of PUF60 has been associated with the 
progression of T-ALL in a mouse model with homozygous deletion of TP53 [20]. However, functional 
studies are needed to elucidate PUF60 role in AML. The fusion gene SAV1-GYPB may be of interest due 
to the role of the tumor suppressor SAV1 [45]. SAV1 interacts with two kinases MST1 and MST2 to form 
an active protein complex and promotes cell-cycle exit. The ability of SAV1 to binds MST1/MST2 is limited 
to the functionality of its coiled-coil domain. In this scenario, the identified translocation impaired the 
coiled-coil domain, suggesting the loss of stability of the SAV1-MST1-MT2 complex [46]. 
Data from the TCGA Fusion Gene Database showed that the some of the candidate genes form 
chimeras with a variety of partners in different tumor types, suggesting that they might locate in 
genomic regions prone to chromosomal rearrangements [47,48] and/or have a role in carcinogenesis. 
The most frequently altered genes were CPD and CNOT2, whose overexpression was associated with 
survival, inhibition of apoptosis and angiogenesis in different cancer types [22,49–52]. Regarding the 
other genes that were rarely rearranged across cancer, they might participate to the leukemic 
phenotype, even though not being the driver of transformation. Our AML cohort was characterized 
by mutations in genes with a known pathogenic role in leukemia and the identified chimeras 
contributed to the disease complexity, as demonstrated by the involvement of genes such as WT1 or 
copy-number loss of NF1. 
Finally, we detected three isoforms of the rare fusion transcript ZEB2-BCL11B (sample #59810) 
and its reciprocal BCL11B-ZEB2. Interestingly, the fusion protein ZEB2-BCL11B was previously 
identified in two adult AML cases [29,40] and three paediatric T/M MPAL cases [30], suggesting a 
putative role in leukemogenesis. We described the characterization of five cases carrying the 
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t(2;14)(q22.3;q32.2) translocation involving the rearrangement of ZEB2 and BCL11B. In two of the 
three patients with immunophentoypic characterization, leukemic cells co-expressed T-cells markers 
such as CD3, CD2 and CD7, and one additional case was diagnosed as AUL. Molecular profiling 
revealed that four out of five rearranged patients harboured FLT3-ITD internal tandem duplication, 
and two of these had an allelic fraction < 0.5 and carried a co-occurring alteration in the tyrosine 
kinase domain. These data suggested that FLT3 alterations might arise as a secondary event. In vitro 
expression of the full-length ZEB2-BCL11B transcript in murine c-Kit+ cells did not show evidence of 
transforming ability. This evidence suggests that as for other fusions, additional alterations are 
required for malignant transformation [53,54] and, based on our data, FLT3 alterations might be the 
most promising candidates. The elucidation of the mechanism(s) of leukemogenesis driven by the 
t(2;14)(q22.3;q32.2) translocation deserves further investigation. Recent studies have shed light on the 
role of ZEB2 in normal and malignant haematopoiesis [24,25], suggesting its loss of function or 
aberrant function may also contribute to neoplastic transformation. 
Interestingly, by immunohistochemistry we showed that BLC11B is expressed in the 
t(2;14)(q22.3;q32.2)-rearranged leukemic blasts (patient #59810), but also in nine non-rearranged 
AML cases and two T/M MPAL or AUL with 14q32 rearrangement. This suggests that BCL11B may 
have a role in leukemogenesis. The comparison of gene expression profile from BCL11B+ and BCL11B- 
patients revealed downregulation of genes involved in the innate immune response, inflammatory 
response, leukocyte migration and cell adhesion, leukotriene metabolic pathways and response to 
oxidative stress in BCL11B+ AML patients. Abbas and colleagues showed that BCL11B overexpression 
in 32D myeloid cell line resulted in a decreased proliferation, less maturation toward granulocyte and 
more undifferentiated blast cells [41], but did not detect a transforming ability of BCL11B. Thus, further 
studies are needed to clarify the role of and interplay between the chimeric protein and co-occurring 
alterations in acute leukemia in an effort to identify potential therapeutic targets for these patients. 
4. Materials and Methods 
4.1. Patients and Samples 
The study was approved by the Institutional Ethical Committee (protocol number 
253/2013/O/Tess and 112/2014/U/Tess) of Sant’Orsola-Malpighi Polyclinic (Bologna, Italy) and the 
Internal Review Board of MLL Munich Leukemia Laboratory and was carried out in accordance with 
the ethical standards laid down in the 1964 Declaration of Helsinki. Samples from adult patients with 
primary adult AML were obtained after informed consent. 
Leukocytes were enriched by separation on Ficoll density gradient and lysed in RLT buffer. 
Genomic DNA and RNA were extracted by column purification (AllPrep DNA/RNA/Protein Mini 
Kit and QIAcube, or RNeasy Mini Kit, Qiagen, Hilden, Germany). 
4.2. Chromosome Banding Analysis (CBA) 
CBA was performed as previously described [55]. Karyotypes were examined after GAW or 
GAG banding technique and described according to International System for Human Cytogenomic 
Nomenclature (ISCN 2016) [56]. 
4.3. Fluorescent In Situ Hybridization (FISH) 
FISH analysis was carried out on fixed nuclei obtained using the CBA technique according to 
the manufacturer’s instructions. Dual color breakapart FISH probes created with the BAC clones 
RP11-644D8 and RP11-360D1 (covering up- and down-stream regions of the ZEB2 gene) and with 
RP11-1147k11 and RP11-464J3 (covering the up- and down-stream regions of the BCL11B gene), was 
used to identify ZEB2 and BCL11B rearrangements, respectively. To identify the specific ZEB2-
BCL11B fusion gene, a dual color single fusion was obtained using RP11-644D8 and RP11-464J3 
clones. BAC clones were provided already marked in Spectrum Orange or Spectrum Green (Empire 
Genomics, New York, NY, USA). The slides were counterstained with DAPI and analysed using 
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fluorescent-microscopes equipped with FITC/TRITC/AQUA/DAPI filter sets and the Genikon imaging 
system software (Nikon Instruments, Tokyo, Japan). At least 100 nuclei were analysed for each sample. 
4.4. Sequencing and Fusion Detection 
Libraries for RNA-seq were prepared with the TruSeq stranded mRNA kit (Illumina, San Diego, 
CA, USA) following manufacturer’s instructions. RNA-seq libraries were subjected to 2 × 75 bp 
paired-end sequencing and run on a HiSeq 2500 or 1000 instrument (Illumina), and following 
manufacturer’s specifications. An average of 50 million reads per sample was obtained. Targeted 
DNA sequencing of myeloid-related genes was performed using the TruSight Myeloid Sequencing 
Panel (Illumina) and run on a MiSeq instrument (Illumina). Variants with a total read depth > 500 
and falling into exonic regions and splice sites were retained. Targeted sequencing of ZEB2-BCL11B 
rearranged patients was performed as previously described [40]. 
Fusion genes were detected on RNA-seq data by applying FuGePrior pipeline to the gene fusion 
lists provided by ChimeraScan [57] and deFuse [58] tools. According to FuGePrior workflow [59], 
fusions with the following features were removed: (i) not supported by split reads (i.e., reads 
harboring the fusion breakpoint); (ii) involving at least one unannotated partner gene; (iii) shared by 
healthy samples; (iv) characterized by a non-reliable structure; (v) having at least the driver score 
probability lower than 0.7. The DS score was a measure of the probability of the fusion being an 
oncogenic event, according to Pegasus [60] and Oncofuse [61]. 
Firstly, we screened the putative fusions list to identify chimeras originating from chromosomal 
translocations detected by the cytogenetic analysis (tier 1). Secondly, to identify cryptic fusions and 
to reduce the number of false-positive predictions, we implemented additional filters to remove: (i) 
recurrently fused genes showing a large diversity among partner genes (including HBB, HBA, HBD, 
MPO, DLG2) [62]; (ii) conjoined genes; (iii) fusions recurring in more than one sample in our cohort. 
We added the latter criteria as we assumed it was not likely to found a recurrent fusion in such a 
small and heterogeneous cohort. Then, in order to identify cryptic but relevant fusions, we prioritized 
chimeras according to the probability of the transcript being an oncogenic event (tier 2). Finally, we 
rescued out-of-frame fusions (DS < 0.7) involving tumor suppressor genes (tier 3) to identify loss of 
function alterations in key genes. The recurrent gene fusion CBFB-MYH11 was identified in the 
positive control (sample #84), thus confirming the reliability of our bioinformatic analysis. The dataset 
supporting the conclusions of this article is available in the NGS-PTL repository, at the following link: 
https://ngs-ptl.unibo.it:5006. 
For expression analysis, raw data were aligned to the reference genome and read counts were 
normalized using the DESeq2 package and the rlog transformation for data normalization [63]. 
Differentially expressed genes, median absolute deviation calculations, unsupervised clustering and 
expression plots were performed using R packages limma [64], DescTools, ComplexHeatmap [65] 
and ggplot2, respectively. Enrichment pathway analysis was performed with Enrichr [66]. 
4.5. RT-PCR, PCR, qPCR and Sanger Sequencing 
cDNA synthesis was performed using M-MLV Reverse Transcriptase for primary AML samples 
and Random Hexamers (Invitrogen, Thermo Fisher, Waltham, MA, USA) or the SuperScript III First-
Strand Synthesis System (Invitrogen) for RNA extracted from transduced c-Kit+ cells. Polymerase 
chain reaction (PCR) primers were designed to amplify fragments containing the fusion boundary 
detected by RNA-seq using Primer3 (http://primer3.ut.ee/, Table S1). Quantitative PCR (qPCR) was 
performed using Brilliant III Ultra-Fast QPCR Master Mix (Agilent Technologies, Santa Clara, CA, USA) 
on an Mx3000p qPCR system (Agilent Technologies) and standard cycling set-up (Table S1). TaqMan 
gene expression for BCL11B mRNA (Hs01102259_m1) was performed on BM cells from AML patients 
(blasts ≥ 80%, n = 10) and peripheral blood mononuclear cells from healthy controls (n = 3), using 
GAPDH (Hs02786624_g1) as reference gene, on the Applied Biosystems 7500 Real-Time PCR System 
(Thermo Fischer Scientific). Gene expression was quantified by the 2-ΔΔCt method, using the average 
of healthy controls as reference sample. Long-distance PCR were performed with LA Taq DNA 
Polymerase (Takara Bio, Shiga, Japan) following manufacturer instructions for human genomic 
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DNA. Fast Start Taq DNA Polymerase (Roche, Basel, Switzerland) was used for standard PCR 
reactions. Products were purified with the QIAquick PCR purification kit (Qiagen) or conventional 
agarose gel electrophoresis and extraction of specific bands with the QIAquick Gel Extraction kit (Qiagen). 
PCR products were sequenced by Sanger Sequencing using an ABI PRISM 3730 automated DNA 
sequencer (Applied Biosystems) and the Big Dye Terminator DNA sequencing kit (Applied Biosystems, 
Foster City, CA, USA). Fusion detection was performed using NCBI Blast alignment and BLAT software 
tool (http://genome.ucsc.edu/cgi-bin/hgBlat?command=start) to reference genome GRCh37/hg19. 
BCR and TCR clonality assay was performed as described by the BIOMED-2 study[67]. 
4.6. Immunohistochemistry 
BM specimens were fixed in B5 solution for 2 hours, decalcified with EDTA-based solution for 
3 hours and paraffin embedded. Histological stainings were examined (Hematoxylin&Eosin, Giemsa, 
Gomori silver impregnation) and 3 μm-thick sections were cut for immunohistochemistry. The 
antigen retrieval methods used were heat-based Pt-Link (Agilent Technologies, PT100/PT101) and 
EnVision Flex Target Retrieval Solution High pH (Agilent Technologies, K8004) at 92 °C or 82 °C. All 
samples were stained for the following molecules: CD34 (mouse monoclonal, clone END, NCL-L-
END,1:100, Microsystems, Newcastle, UK), myeloperoxidase (rabbit polyclonal, A0398, 1:5000, 
Agilent Technologies), CD68 (mouse monoclonal, clone PGM1, 1:5, kindly provided by Prof. Falini, 
Perugia, Italy), BCL11B (rabbit polyclonal, NB100-2600, 1:200, Novus Biologicals Centennial, CO, 
USA). The BCL11B antibody was validated on reactive bone marrow and nodal follicular hyperplasia. 
The staining panels on the AML cases were performed using positive (the same sample for validation) 
and negative controls (slides with exclusion of the primary antibody). The analysis of CD34 and CD68 
antibodies were performed according to long standing previously settled procedures. 
The reaction detection was performed by using the Dako Real Detection Systems Alkaline 
Phosphatase/RED Rabbit/Mouse Kit (K 5005, Agilent Technologies). Overall, 24 BM biopsies were 
analysed. One BM biopsy referred to case #59810 with t(2;14), 21 BM biopsies referred to 21 AML 
patients without t(2;1) and/or 14q32 rearrangement, 2 BM biopsies referred to patients with 14q32 
rearrangements (Table S6). 
4.7. Gene Expression Profiling (GEP) and SNP-Array 
We analysed gene expression and copy number data from a previously obtained internal cohort [55]. 
Gene expression raw data were processed by Expression Console software with Signal Space 
Transformation Robust Multi-Array average (sst-RMA) normalization. Supervised data analysis was 
carried out with Transcriptome Analysis Console v4.0 software (Affymetrix, Thermo Fisher). 
Functional annotation clustering and enrichment analysis was performed using David Bioinformatics 
Resources 6.8 (National Institute of Allergy and Infectious Diseases, NIH) [68]. CEL files from SNP-
array raw intensities were processed using Rawcopy[69]. 
4.8. Retroviral Transduction Assays 
The TY1-tagged full length transcripts ZEB2-BCL11B was subcloned into a retroviral vector 
using EcoRI restriction sites. The resulting plasmid’s sequence was verified by Sanger sequencing. 
Murine stem cell virus–based (MSCV-based) retroviral constructs carrying the tagged ZEB2-BCL11B 
sequence upstream of an internal ribosomal entry site–green fluorescent protein (IRES-GFP) cassette 
were generated using 293T packaging cell line. Vectors containing the fusion gene (ZEB2-BCL11B), 
the MLL-AF9 fusion (acting as positive control) or the empty vector (negative control) were used to 
transduce mouse c-Kit+ BM cells. Mouse whole BM was positively selected with the CD117 (c-Kit) 
MicroBeads and the LS MACS column according manufacturer´s instructions (Miltenyi Biotec, 
Bergisch Gladbach, Germany). Retroviral transduction was performed as previously described[70]. 
4.9. Serial Colony Replating Assay 
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Colony forming unit assay was performed in duplicates by seeding 1000 c-Kit+ transduced cells 
in Methocult M3434 methylcellulose medium (StemCell Technologies, Vancouver, BC, Canada). Cells 
were plated in duplicate and after 7–12 days colonies were scored, pooled and identical numbers of 
cells were re-plated under the same conditions. 
4.10. Flow Cytometry Analysis 
Multiparameter flow cytometry (MFC) and sample processing was carried out as described 
previously[71]. MFC analyses were performed using FC500 or Navios flow cytometers (Beckman 
Coulter, Miami, FL, USA). List mode files were analyzed using CXP Software version 2.0 and Kaluza 
version 1.0 (Beckman Coulter, Brea, CA, USA). Diagnoses were assigned according to EGIL and 
WHO classifications [10,72]. Single cell suspensions of transduced c-Kit+ cells were prepared as 
described elsewehere [15]. Dead cells were excluded by gating on 7AAD (Miltenyi Biotec)-negative 
cells. Flow cytometry analysis were performed on an LSR Fortessa cell analyser (BD Biosciences, San 
Jose, CA, USA) and data were analysed with FlowJo software v 10 (BD, Franklin Lakes, NJ, USA). 
4.11. Immunoblotting 
Whole-cell lysates were prepared from 107 cells in 6× Laemmli buffer. Lysates were run on SDS–
PAGE gels and transferred to PVDF membranes (Millipore). Membranes were probed with the anti-
Gapdh (Abcam, Cambridge, UK), anti-TY1 (Thermo Fisher Scientific) and anti-BCL11B (Abcam) 
primary antibodies at 1:10000, 1:2000 and 1:10000 dilutions, respectively. Membranes were probed 
with secondary antibodies conjugated to IRDye 680RD or IRDye 800 CW (LI-COR Biosciences Ltd. 
Lincoln, NE, USA) at 1:10000 dilution and proteins were detected using the Odyssey Infrared 
Imaging System (LI-COR Biosciences Ltd). Restore Western Blot Stripping Buffer (Thermo Fisher 
Scientific) were used to remove primary and secondary antibodies from PVDF membrane in order to 
reprobe with the anti-BCL11B antibody. 
5. Conclusions 
Fusion genes are frequently detected in cancer and they are often the result of chromosomal 
rearrangements such as translocations, inversions and deletions, all of which may involve a single 
chromosome or different chromosomes. Here we reported the identification of novel gene fusion 
events in AML. Although the pathogenic role and functional properties of these alterations will 
require additional functional studies, here we demonstrated that ZEB2-BCL11B rearrangement is 
recurrent and associated with distinct immune-clinico characteristics. 
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